Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

Rectal Cancer Clinical Trial

Official title:

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01460641
• Other study ID #: REC0006
• Secondary ID: SU-10202011-8538
• Status: Completed
• Start date: November 2011
• Est. completion date: July 2018

Study information

• Verified date: September 2018
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.

Description:

Recent advances in computed tomography (CT) technology have made CT perfusion imaging feasible for the assessment of tumor perfusion in solid tumors of the abdomen. CT perfusion has shown promising results in serving as a noninvasive method of predicting response to therapy in cancer patients. CT perfusion parameters have also been found to correlate with immunohistologic markers of angiogenesis in a number of solid tumors, suggesting a possible role for CT perfusion as a noninvasive biomarker of tumor angiogenesis. The goals of the investigators study are twofold: first, to determine the relationship between baseline CT perfusion characteristics of rectal cancers and their response to treatment, and second, to determine if perfusion CT can be used to subsequently monitor tumor response to treatment. The investigators hope to enroll those patients with locally advanced rectal cancer undergoing standard CT for pre-treatment planning, integrating CT perfusion imaging into the current abdomen/pelvis imaging protocol with close clinical and radiologic follow-up after treatment to determine response to therapy and time to disease progression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 2018
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with suspected or biopsy-proven, locally advanced rectal cancer will be eligible for enrollment.

• Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant.

• No life expectancy restrictions.

• ECOG and Karnofsky Performance Status will not be employed.

• Patients with renal failure are ineligible for this study (GFR must be > 60)

• Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients who have undergone prior treatment for rectal cancer are ineligible for enrollment.

• No restrictions regarding use of other investigational agents.

• Patients with severe contrast allergy are ineligible.

• Patients who are pregnant or are trying to become pregnant are excluded from this study.

• Patients who are cancer survivors or HIV-positive will not be excluded.

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

Locations

Country	Name	City	State
United States	Stanford University, School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor stage change from Computed Tomography (CT) perfusion measurement		3 months
Secondary	Tumor perfusion as measured by perfusion CT.		1 year